Kelly John Alexander 4

What Happened

• Kelly John Alexander, Chief Financial Officer of Precision BioSciences (DTIL), had 27,584 Restricted Stock Units (RSUs) vest on Feb 17, 2026 (treated as an acquisition at $0.00) and sold 8,149 of the resulting shares on Feb 18, 2026 at $3.84 each for proceeds of $31,292. The sale was a sell-to-cover to satisfy tax withholding obligations tied to the RSU settlement.

Key Details

• Transaction dates and prices:
  • Feb 17, 2026: 27,584 RSUs vested => 27,584 shares acquired at $0.00 (award settlement).
  • Feb 18, 2026: 8,149 shares sold open market/private sale at $3.84 each for $31,292.
• Net effect: 27,584 shares vested and 8,149 sold to cover taxes → net increase of 19,435 shares retained from this vesting event.
• Footnotes: Sales were effected under a Rule 10b5-1 plan adopted Jan 17, 2025 and were explicitly sell-to-cover for tax withholding. Each RSU equals one share; RSUs vest in three substantially equal annual installments beginning Feb 17, 2026.
• Filing: Form 4 filed Feb 19, 2026 (appears to be filed within the standard two-business-day window).

Context

• This was not a discretionary sell for liquidity or investment judgment — the sale was to meet tax-withholding tied to RSU vesting under a pre-established 10b5-1 plan. For retail investors, routine sell-to-cover transactions are common following awards and do not necessarily signal management’s view of the stock.